SOAT1 and Granuloma: JAK inhibitor was chosen based on the new studies that show the implication of Janus kinase–signal transducer and activator of transcription (JAK–STAT) pathway in the pathogenesis of granuloma formation and its possible effect in patients with AG [19], in addition to recent reports of treating patients with AG with baricitinib [20].